Etanercept therapy in patients with autoimmunity and hepatitis C.
Accumulated data suggest that etanercept may be a therapeutic option in patients with hepatitis C and coexisting autoimmune disorders such as rheumatoid arthritis, psoriasis, psoriatic arthritis and ankylosing spondylitis. Additionally, etanercept may actually be of benefit, when used in combination with standard treatments, for hepatitis C.
Khanna
M
M
Department of Medicine and Clinical Research Center, UMDNJ-Robert Wood Johnson Medical School, 51 French Street, New Brunswick, NJ 08901-0019, USA.
Shirodkar
M A
MA
Gottlieb
A B
AB
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000188:drug therapy; D018849:Controlled Clinical Trials as Topic; D004195:Disease Models, Animal; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007372:Interferons / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000998:Antiviral Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D007372:Interferons; D000068800:Etanercept